I certainly wouldn't characterize you as a curiosity seeker - you are way too informed. Your optimism about cabo parallels my views and I would not describe our enthusiasm as irrational.
I think there's been so much focus on bone met resolution that efficacy on tumor control, independent of bone effects, has been deemphasized. Maybe MM saw an opportunity to say something about PFS or some other readout and he spoke up.
pure speculation on my part but stick a microphone in my face and I have a tendency to tell you everything I know, regardless of the script..... or at least everything that's on my mind. My seminars tend to ramble according to questions being asked. It may not have been intentional on MM's part.
I also felt shafted by the BMY/MEDX deal and feel karma was at play when BMY handed cabo back to EXEL. In my view, chances of some low-ball, back-door deal with EXEL are nil. Way too many success stories and too much potential. Looks like management is willing to play this out in the clinical trial arena. MEDX's CTLA-4 blockade had a few incredible patient responses but mostly failed responses; presumably due to patients immune systems being devastated by prior chemotherapy treatments. FDA let them adjust their clinical trial end points in middle of trials, as I recall, based on some of the exceptional responses. There were and are huge safety concerns about CTLA-4 blockade. Several patients have died from uncontrolled immune responses directly attributed to Ipilimumab treatment since it has been approved by FDA. Ipilimumab had not even completed a Phase III trial when it was sold to BMY in a sleazy deal. You cannot overstate the importance of cabo already being FDA approved in terms of it's valuation. All subsequent studies can use previous studies to build a case for safety and efficacy.
I've said it before, as soon as one Pharm makes an offer - there will be a bidding war. All Pharms have different needs and will have a different calculus as to it's value. Problem is it's damn near impossible to place a value on EXEL as a whole or any of it's parts - again, too much potential, too many questions and too many moving parts..... today. Valuations that Pharm can live with will start to become more clear with ongoing trials.
Then the fireworks start.
yes, you are seeing this correctly. My prediction falls exactly along your lines of thinking. Oncologists will avoid using Ra223 if cabo were available.
AACR has always emphasized early, discovery research. EXEL is at the next level and all important results/news (that isn't in the form of a press release) will be at ASCO.
wilder, thanks for all your work and esp. your humor....
thanks for the note. I was born in Big Sky, raised in Colorado but have been in NYC area for 27+ yrs. Boston is huge change for me. Group that recruited me are a bunch of folks from what was once Rosetta and there is a heavy emphasis on genomic analysis. genomics is the driving force behind everything these days and we are still just beginning. yeah, still hanging w SQNM and have been adding at these prices. SQNM will come out on the right side of this legal @%*#$ if there's any justice in this world and then we'll take off.
like cement says: patience with an attitude.
... to see robo posting and thumbs-down continuing as SQNM's sp hovers around $2. Somebody is expending significant time/effort to ensure nothing meaningful gets posted here - too bad. This mb was once informative as well as entertaining; esp. viorel. all this spamming will be futile in the long run. we longs just need to be patient and buy more. this price is a gift.
that's what I said. Charles doesn't have the time or patience to deal with the tedium required in standardizing a clinical app.. But he can point Dirk in the right direction n a two minute phone conversation.
Charles is a chemist after all. Youngest person to ever be Chairman of Chemistry dept. at Columbia. I know from direct experience he excels in minute details of sample prep and now NGS. This is all about chemistry - physical and bio. Charles has more knowledge at his fingertips than Dirk will have 20 years from now. He doesn't need to be around on a daily basis for SQNM's success. He remains a huge asset as they gear up for more cancer diagnosis.
Oh yeah, he's always out-of-town. Been trotting the globe for decades now. He has always been in huge demand. Nothing has changed.